Lung Therapeutics closes $36M series C  Lung Therapeutics Inc. (Austin, Texas) raised $36 million in a series C round led by Bios Partners with participation by undisclosed new and existing investors. Lung has raised $53...

HHS’s Biomedical Advanced Research and Development Authority and Genentech Inc. partnered to develop products to fight influenza and other health security threats. BARDA initially will provide $43 million over five years to develop baloxavir marboxil...

Alxerion Biotech LLC is building a biobank of exosomes from diverse species as a comprehensive source for therapeutics discovery. Its initial focus is on cancer. The company aims to collect and screen 350,000 samples from...

HHS’s Biomedical Advanced Research and Development Authority and Genentech Inc. partnered to develop products to fight influenza and other health security threats. BARDA initially will provide $43 million over five years to develop baloxavir marboxil...

INDICATION: Sarcoma; pancreatic cancer In vitro and mouse studies identified an amiloride-based PLAU inhibitor that could help treat metastatic fibrosarcoma and pancreatic cancers. Chemical synthesis and in vitro testing of amiloride analogs in enzyme activity...

Ionis Pharmaceutics Inc. (NASDAQ:IONS) and The Rockefeller University found blood plasmin drives Alzheimer's disease progression and immune responses in the brain, shedding light on neuroinflammation's role in AD. The team suggested antisense oligonucleotide depletion of...

TECHNOLOGY: Nanoparticles Nanoparticles bound to red blood cells (RBCs) could be used to deliver drugs to the vasculature of specific organs. The method involves mixing bare nanogels with ex vivo RBCs to enable RBC-nanoparticle binding,...

TECHNOLOGY: Cell therapy A biomanufacturing method could enable ex vivo production of human platelets to treat thrombocytopenia and other hematologic indications. In human induced pluripotent stem (iPS) cell-derived megakaryocyte cell lines cultured in shaking flasks,...

INDICATION: Stroke Patient sample and mouse studies suggest a factor H-CR2 conjugate that inhibits C3d deposition could help treat stroke. In postmortem brain samples from three patients, deposition of C3d was higher in the perilesional...

While the biggest milestone of the second quarter came early and turned out to be a disappointment, investors still have plenty to look forward to in immuno-oncology. In addition, specialist investors’ current strategy of overweighting...